keyword
MENU ▼
Read by QxMD icon Read
search

"glioblastoma" radiotherapy

keyword
https://www.readbyqxmd.com/read/28223165/heterogeneous-intratumoral-distribution-of-gadolinium-nanoparticles-within-u87-human-glioblastoma-xenografts-unveiled-by-micro-pixe-imaging
#1
Asuncion Carmona, Stéphane Roudeau, Baptiste L'Homel, Frédéric Pouzoulet, Sarah Bonnet-Boissinot, Yolanda Prezado, Richard Ortega
Metallic nanoparticles have great potential in cancer radiotherapy as theranostic drugs since, they serve simultaneously as contrast agents for medical imaging and as radio-therapy sensitizers. As with other anticancer drugs, intratumoral diffusion is one of the main limiting factors for therapeutic efficiency. To date, a few reports have investigated the intratumoral distribution of metallic nanoparticles. The aim of this study was to determine the quantitative distribution of gadolinium (Gd) nanoparticles after direct intratumoral injection within U87 human glioblastoma tumors grafted in mice, using micro-PIXE (Particle Induced X-ray Emission) imaging...
February 18, 2017: Analytical Biochemistry
https://www.readbyqxmd.com/read/28199863/analysis-of-chemopredictive-assay-for-targeting-cancer-stem-cells-in-glioblastoma-patients
#2
Candace M Howard, Jagan Valluri, Anthony Alberico, Terrence Julien, Rida Mazagri, Robert Marsh, Hoyt Alastair, Antonio Cortese, Michael Griswold, Wanmei Wang, Krista Denning, Linda Brown, Pier Paolo Claudio
INTRODUCTION: The prognosis of glioblastoma (GBM) treated with standard-of-care maximal surgical resection and concurrent adjuvant temozolomide (TMZ)/radiotherapy remains very poor (less than 15 months). GBMs have been found to contain a small population of cancer stem cells (CSCs) that contribute to tumor propagation, maintenance, and treatment resistance. The highly invasive nature of high-grade gliomas and their inherent resistance to therapy lead to very high rates of recurrence. For these reasons, not all patients with similar diagnoses respond to the same chemotherapy, schedule, or dose...
February 12, 2017: Translational Oncology
https://www.readbyqxmd.com/read/28197654/temozolomide-during-radiotherapy-of-glioblastoma-multiforme-daily-administration-improves-survival
#3
Silke Birgit Nachbichler, Gabi Schupp, Hendrik Ballhausen, Maximilian Niyazi, Claus Belka
BACKGROUND: Temozolomide-(TMZ)-based chemoradiotherapy defines the current gold standard for the treatment of newly diagnosed glioblastoma. Data regarding the influence of TMZ dose density during chemoradiotherapy are currently not available. We retrospectively compared outcomes in patients receiving no TMZ, TMZ during radiotherapy on radiotherapy days only, and TMZ constantly 7 days a week. PATIENTS AND METHODS: From 2002-2012, a total of 432 patients with newly diagnosed glioblastoma received radiotherapy in our department: 118 patients had radiotherapy alone, 210 had chemoradiotherapy with TMZ (75 mg/m(2)) daily (7/7), and 104 with TMZ only on radiotherapy days (5/7)...
February 14, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28193626/autologous-heat-shock-protein-peptide-vaccination-for-newly-diagnosed-glioblastoma-impact-of-peripheral-pd-l1-expression-on-response-to-therapy
#4
Orin Bloch, Michael Lim, Michael E Sughrue, Ricardo J Komotar, John M Abrahams, Donald M O'Rourke, Anthony D'Ambrosio, Jeffrey N Bruce, Andrew T Parsa
PURPOSE: Standard therapy for newly diagnosed glioblastoma (GBM) is surgical resection, followed by concurrent radiotherapy and temozolomide chemotherapy. In this phase 2 clinical trial, the addition of an autologous heat shock protein vaccine to standard therapy was evaluated. Tumor-induced immunosuppression, mediated by expression of PD-L1 on tumor and circulating immune cells, may impact the efficacy of vaccination. Expression of PD-L1 on peripheral myeloid cells was evaluated for the first time as a predictor of survival...
February 13, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28193559/dual-functional-mesoporous-silicon-nanoparticles-enhance-the-radiosensitivity-of-vpa-in-glioblastoma
#5
Hailong Zhang, Wei Zhang, Yong Zhou, Yuhua Jiang, Shupeng Li
Radiotherapy is a critical strategy and standard adjuvant approach to glioblastoma treatment. One of the major challenges facing radiotherapy is to minimize radiation damage to normal tissue without compromising therapeutic effects on cancer cells. Various agents and numerous approaches have been developed to improve the therapeutic index of radiotherapy. Among them, radiosensitizers have attracted much attention because they selectively increase susceptibility of cancer cells to radiation and thus enhance biological effectiveness of radiotherapy...
February 10, 2017: Translational Oncology
https://www.readbyqxmd.com/read/28192785/temozolomide-with-or-without-radiotherapy-in-patients-with-newly-diagnosed-glioblastoma-multiforme-a-meta-analysis
#6
Enshan Feng, Changbai Sui, Tongxin Wang, Gaoling Sun
BACKGROUND/AIM: The current meta-analysis evaluated the survival outcomes of newly diagnosed glioblastoma patients treated with radiotherapy (RT) alone and with RT + temozolomide (TMZ). METHODS: Relevant studies were identified by an extensive literature search in Medline, Current Contents and Cochrane databases by 2 independent reviewers using the terms "glioblastoma multiforme/glioblastoma, TMZ, radiation therapy/RT and survival." RESULTS: Results revealed a median survival of 13...
February 14, 2017: European Neurology
https://www.readbyqxmd.com/read/28188088/high-dose-neural-stem-cell-radiation-may-not-improve-survival-in-glioblastoma
#7
R Achari, M Arunsingh, R K Badgami, A Saha, S Chatterjee, R K Shrimali, I Mallick, B Arun
AIMS: To evaluate the effect of radiotherapy dose-volume parameters of neural stem cell (NSC) compartment on progression-free survival (PFS) and overall survival after post-resection chemoradiation in newly diagnosed glioblastoma. MATERIALS AND METHODS: Sixty-one patients with unifocal glioblastoma were included. Ipsilateral (NSC_Ipsi), contralateral (NSC_Contra) and combined NSC (NSC_Combined) were contoured on radiotherapy planning computerised tomography datasets...
February 8, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28176936/add-on-bevacizumab-can-prevent-early-clinical-deterioration-and-prolong-survival-in-newly-diagnosed-partially-resected-glioblastoma-patients-with-a-poor-performance-status
#8
Nobuhiro Hata, Koji Yoshimoto, Ryusuke Hatae, Daisuke Kuga, Yojiro Akagi, Yuhei Sangatsuda, Satoshi O Suzuki, Tadahisa Shono, Masahiro Mizoguchi, Koji Iihara
PURPOSE: The AVAglio trial established the beneficial effect of add-on bevacizumab (BEV) for the treatment of newly diagnosed glioblastomas (nd-GBMs) that led to the approval of BEV for the treatment of these patients in Japan. However, the rationality of using BEV as a first-line treatment for nd-GBMs remains controversial. The purpose of this study was to analyze the outcomes of a case series of nd-GBM patients. PATIENTS AND METHODS: The outcomes of 69 nd-GBM patients treated after 2006 were retrospectively analyzed...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28176884/impact-of-including-peritumoral-edema-in-radiotherapy-target-volume-on-patterns-of-failure-in-glioblastoma-following-temozolomide-based-chemoradiotherapy
#9
Seo Hee Choi, Jun Won Kim, Jee Suk Chang, Jae Ho Cho, Se Hoon Kim, Jong Hee Chang, Chang-Ok Suh
We assessed the impact of including peritumoral edema in radiotherapy volumes on recurrence patterns among glioblastoma multiforme (GBM) patients treated with standard chemoradiotherapy (CRT). We analyzed 167 patients with histologically confirmed GBM who received temozolomide (TMZ)-based CRT between May 2006 and November 2012. The study cohort was divided into edema (+) (n = 130) and edema (-) (n = 37) groups, according to whether the entire peritumoral edema was included. At a median follow-up of 20 months (range, 2-99 months), 118 patients (71%) experienced progression/recurrence (infield: 69%; marginal: 26%; outfield: 16%; CSF seeding: 12%)...
February 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28160825/-glioblastoma-in-2017
#10
Hugues Duffau
Glioblastomas are serious tumours of the central nervous system. Recurrence is systematic and prognosis poor. Radiotherapy and chemotherapy follow surgery, when surgery is possible, to lengthen survival, while preserving quality of life as much as possible. In this respect, symptomatic treatments and supportive care are necessary.
February 2017: Revue de L'infirmière
https://www.readbyqxmd.com/read/28153049/longitudinal-analysis-of-treatment-induced-genomic-alterations-in-gliomas
#11
E Zeynep Erson-Omay, Octavian Henegariu, S Bülent Omay, Akdes Serin Harmancı, Mark W Youngblood, Ketu Mishra-Gorur, Jie Li, Koray Özduman, Geneive Carrión-Grant, Victoria E Clark, Caner Çağlar, Mehmet Bakırcıoğlu, M Necmettin Pamir, Viviane Tabar, Alexander O Vortmeyer, Kaya Bilguvar, Katsuhito Yasuno, Lisa M DeAngelis, Joachim M Baehring, Jennifer Moliterno, Murat Günel
BACKGROUND: Glioblastoma multiforme (GBM) constitutes nearly half of all malignant brain tumors and has a median survival of 15 months. The standard treatment for these lesions includes maximal resection, radiotherapy, and chemotherapy; however, individual tumors display immense variability in their response to these approaches. Genomic techniques such as whole-exome sequencing (WES) provide an opportunity to understand the molecular basis of this variability. METHODS: Here, we report WES-guided treatment of a patient with a primary GBM and two subsequent recurrences, demonstrating the dynamic nature of treatment-induced molecular changes and their implications for clinical decision-making...
February 2, 2017: Genome Medicine
https://www.readbyqxmd.com/read/28150230/melanocortin-receptor-4-gene-polymorphisms-in-glioblastoma-patients-treated-with-concomitant-radio-chemotherapy
#12
Francesco Pasqualetti, Paola Orlandi, Vittorio Simeon, Martina Cantarella, Daniela Giuliani, Teresa Di Desidero, Alessandra Gonnelli, Durim Delishaj, Giuseppe Lombardi, Andrea Sechi, Marc Sanson, Vittorina Zagonel, Fabiola Paiar, Romano Danesi, Salvatore Guarini, Guido Bocci
Melanocortins are peptides with well-recognized antiinflammatory and neuroprotective activity. No data are currently available on melanocortin receptor-4 (MC4R) gene polymorphisms and tumors, including glioblastomas (GBMs), or their relationship with radiotherapy or chemotherapy. The aim of this study was to evaluate the possible predictive/prognostic role of the MC4R SNPs on GBM patients. Fifty-five patients with a proven diagnosis of GBM, treated with radiotherapy and temozolomide, were consecutively enrolled...
February 1, 2017: Molecular Neurobiology
https://www.readbyqxmd.com/read/28143434/combination-of-ivim-dwi-and-3d-asl-for-differentiating-true-progression-from-pseudoprogression-of-glioblastoma-multiforme-after-concurrent-chemoradiotherapy-study-protocol-of-a-prospective-diagnostic-trial
#13
Zhi-Cheng Liu, Lin-Feng Yan, Yu-Chuan Hu, Ying-Zhi Sun, Qiang Tian, Hai-Yan Nan, Ying Yu, Qian Sun, Wen Wang, Guang-Bin Cui
BACKGROUND: Standard therapy for Glioblastoma multiforme (GBM) involves maximal safe tumor resection followed with radiotherapy and concurrent adjuvant temozolomide. About 20 to 30% patients undergoing their first post-radiation MRI show increased contrast enhancement which eventually recovers without any new treatment. This phenomenon is referred to as pseudoprogression. Differentiating tumor progression from pseudoprogression is critical for determining tumor treatment, yet this capacity remains a challenge for conventional magnetic resonance imaging (MRI)...
February 1, 2017: BMC Medical Imaging
https://www.readbyqxmd.com/read/28142059/intracerebral-injection-of-cpg-oligonucleotide-for-patients-with-de-novo-glioblastoma-a-phase-ii-multicentric-randomised-study
#14
Renata Ursu, Alexandre Carpentier, Philippe Metellus, Vincent Lubrano, Florence Laigle-Donadey, Laurent Capelle, Jacques Guyotat, Olivier Langlois, Luc Bauchet, Kristell Desseaux, Annick Tibi, Olivier Chinot, Jérôme Lambert, Antoine F Carpentier
BACKGROUND: Immunostimulating oligodeoxynucleotides containing unmethylated cytosine-guanosine motifs (CpG-ODN) have shown a promising efficacy in several cancer models when injected locally. A previous phase II study of CpG-ODN in patients with recurrent glioblastoma (GBM) has suggested some activity and has shown a limited toxicity. This multicentre single-blinded randomised phase II trial was designed to study the efficacy of a local treatment by CpG-ODN in patients with de novo glioblastomas...
March 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28134383/gold-nanotriangles-scale-up-and-x-ray-radiosensitization-effects-in-mice
#15
S R Bhattarai, P J Derry, K Aziz, P K Singh, A M Khoo, A S Chadha, A Liopo, E R Zubarev, S Krishnan
In the past decade, there has been considerable interest in radiosensitization using gold nanoparticles that accumulate specifically in cancerous tissue while sparing normal tissues. Despite this interest, it remains unclear which nanoparticle morphologies, cellular uptake, or cytoplasmic distribution elicit optimal radiosensitization. We introduce gold nanotriangles (AuNTs) as a possible X-ray radiotherapy sensitizer. In this study, we first explored a large-scale synthetic method for the production of high quality monodisperse AuNTs...
January 30, 2017: Nanoscale
https://www.readbyqxmd.com/read/28123740/efficacy-of-bevacizumab-therapy-for-unresectable-malignant-glioma-a-retrospective-analysis
#16
Hajime Yonezawa, Hirofumi Hirano, Hiroyuki Uchida, Mika Habu, Ryosuke Hanaya, Tatsuki Oyoshi, Yuko Sadamura, Tomoko Hanada, Hiroshi Tokimura, Fm Moinuddin, Kazunori Arita
Bevacizumab (BEV), an inhibitor of vascular endothelial growth factor A, has been used for primary and recurrent malignant gliomas in Japan since June, 2013. Previous randomized controlled studies demonstrated that BEV prolonged the progression-free survival, but not the overall survival (OS) of patients with newly diagnosed glioblastoma. The aim of the present study was to elucidate the effect of BEV on the OS of patients with unresectable malignant gliomas. Of the 440 cases of malignant glioma initially treated in our institute between 2000 and 2015, 88 were not suitable for maximal resection due to patient age, physical condition, tumor location and extent, or the patient's wishes...
January 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28113925/personalized-radiotherapy-planning-based-on-a-computational-tumor-growth-model
#17
Matthieu Le, Herve Delingette, Jayashree Kalpathy-Cramer, Elizabeth R Gerstner, Tracy Batchelor, Jan Unkelbach, Nicholas Ayache
In this article, we propose a proof of concept for the automatic planning of personalized radiotherapy for brain tumors. A computational model of glioblastoma growth is combined with an exponential cell survival model to describe the effect of radiotherapy. The model is personalized to the magnetic resonance images (MRIs) of a given patient. It takes into account the uncertainty in the model parameters, together with the uncertainty in the MRI segmentations. The computed probability distribution over tumor cell densities, together with the cell survival model, is used to define the prescription dose distribution, which is the basis for subsequent Intensity Modulated Radiation Therapy (IMRT) planning...
November 8, 2016: IEEE Transactions on Medical Imaging
https://www.readbyqxmd.com/read/28110959/patterns-of-failure-for-patients-with-glioblastoma-following-o-2-18-f-fluoroethyl-l-tyrosine-pet-and-mri-guided-radiotherapy
#18
Michael Lundemann, Junia Cardoso Costa, Ian Law, Svend Aage Engelholm, Aida Muhic, Hans Skovgaard Poulsen, Per Munck Af Rosenschold
BACKGROUND AND PURPOSE: To evaluate the patterns of failure following clinical introduction of amino-acid O-(2-[(18)F]fluoroethyl)-L-tyrosine (FET)-PET-guided target definition for radiotherapy (RT) of glioblastoma patients. MATERIALS AND METHODS: The first 66 consecutive patients with confirmed histology, scanned using FET-PET/CT and MRI were selected for evaluation. Chemo-radiotherapy was delivered to a volume based on both MRI and FET-PET (PETvol). The volume of recurrence (RV) was defined on MRI data collected at the time of progression according to RANO criteria...
January 19, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28103265/rabbit-model-of-human-gliomas-implications-for-intra-arterial-drug-delivery
#19
Huamin Qin, Miroslaw Janowski, Monica S Pearl, Izabela Malysz-Cymborska, Shen Li, Charles G Eberhart, Piotr Walczak
The prognosis for malignant brain tumors remains poor despite a combination of surgery, radiotherapy, and chemotherapy. This is partly due to the blood-brain barrier, a major obstacle that prevents therapeutic agents from effectively reaching the tumor. We have recently developed a method for precise and predictable opening of the blood-brain barrier via the intra-arterial administration of mannitol, a hyperosmolar agent, in a rabbit model, whose vascular anatomy facilitates the use of standard interventional neuroradiology techniques and devices...
2017: PloS One
https://www.readbyqxmd.com/read/28101701/early-postoperative-tumor-progression-predicts-clinical-outcome-in-glioblastoma-implication-for-clinical-trials
#20
Andreas Merkel, Dorothea Soeldner, Christina Wendl, Dilek Urkan, Joji B Kuramatsu, Corinna Seliger, Martin Proescholdt, Ilker Y Eyupoglu, Peter Hau, Martin Uhl
Molecular markers define the diagnosis of glioblastoma in the new WHO classification of 2016, challenging neuro-oncology centers to provide timely treatment initiation. The aim of this study was to determine whether a time delay to treatment initiation was accompanied by signs of early tumor progression in an MRI before the start of radiotherapy, and, if so, whether this influences the survival of glioblastoma patients. Images from 61 patients with early post-surgery MRI and a second MRI just before the start of radiotherapy were examined retrospectively for signs of early tumor progression...
January 18, 2017: Journal of Neuro-oncology
keyword
keyword
75725
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"